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Abstract
Importance—Fusobacterium nucleatum appears to play a role in colorectal carcinogenesis 
through suppression of host immune response to tumor. Evidence also suggests that diet influences 
intestinal F. nucleatum. However, the role of F. nucleatum in mediating the relationship between 
diet and the risk of colorectal cancer is unknown.
Objective—To test the hypothesis that the associations of prudent diets (rich in whole grains and 
dietary fiber) and Western diets (rich in red and processed meat, refined grains, and desserts) with 
colorectal cancer risk may differ according to the presence of F. nucleatum in tumor tissue.
Design—Prospective cohort study.
Setting—The Nurses’ Health Study (1980–2012) and the Health Professionals Follow-up Study 
(1986–2012).
Participants—121,700 US female nurses and 51,529 US male health professionals aged 30 to 55 
years and 40 to 75 years, respectively, at enrollment.
Exposures—Prudent and Western dietary patterns.
Main Outcomes and Measures—Incidence of colorectal carcinoma subclassified by F. 
nucleatum status in tumor tissue, determined by quantitative polymerase chain reaction.
Results—We documented 1,019 incident colon and rectal cancer cases with available F. 
nucleatum data among predominantly white 137,217 individuals over 26–32 years of follow-up 
encompassing 3,643,562 person-years. The association of prudent diet with colorectal cancer 
significantly differed by tissue F. nucleatum status (Pheterogeneity = .01). Prudent diet score was 
associated with a lower risk of F. nucleatum-positive cancers [Ptrend = .003; multivariable hazard 
ratio of 0.43 (95% confidence interval 0.25–0.72) for the highest vs. the lowest prudent score 
quartile], but not with F. nucleatum-negative cancers (Ptrend = .47). Dietary component analyses 
suggested possible differential associations for the cancer subgroups according to intakes of 
dietary fiber (Pheterogeneity = .02). There was no significant heterogeneity between the subgroups 
according to Western dietary pattern scores (Pheterogeneity = .23).
Conclusions and Relevance—Prudent diets rich in whole grains and dietary fiber are 
associated with a lower risk for F. nucleatum-positive colorectal cancer but not F. nucleatum-
negative cancer, supporting a potential role for intestinal microbiota in mediating the association 
between diet and colorectal neoplasms.
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INTRODUCTION
Accumulating evidence suggests that the human gut microbiome is linked to colorectal 
cancer development.1–4 Fusobacterium nucleatum has been found to be enriched in 
colorectal cancer tissue relative to normal adjacent colonic tissue, and is detected at higher 
levels in stool among colorectal cancer cases compared to cancer-free controls.1,5–10 Recent 
experimental data suggest that F. nucleatum may contribute to colorectal carcinogenesis 
through modulation of host immunity and activation of pathways associated with cellular 
proliferation.9,11,12 Furthermore, a higher amount of F. nucleatum in colorectal cancer tissue 
has been linked to shorter survival, proximal tumor location, and specific tumor molecular 
features such as high-level CpG island methylator phenotype and microsatellite 
instability.13–15
Prudent dietary patterns – rich in fruits, vegetables, and whole grains – have been associated 
with a lower risk of colorectal cancer and adenoma, as reviewed in a recent systematic meta-
analysis.16–22 In contrast, Western dietary patterns – dominated by red and processed meats 
– have been linked with colorectal carcinogenesis.16,18 Although mechanisms underlying 
these diet-cancer associations remain unclear, it is postulated that the gut microbiota may 
play a mediating role.23 Recently, in a dietary intervention study, stool F. nucleatum levels 
markedly increased after participants were switched from a prudent-style, high-fiber, low-fat 
diet to a low-fiber, high-fat diet.24 In addition, accumulating data suggest that low fiber 
consumption and high meat intake may be associated with altered bacterial and 
metagenomic profiles as well as an inflammatory phenotype determined by serum levels of 
metabolites.25–28
Based on these findings, we hypothesized that the inverse association between prudent diets 
and risk of colorectal cancer might be more evident for a cancer subgroup enriched with 
tissue F. nucleatum than for that without detectable tissue F. nucleatum. To test this 
hypothesis, we utilized two U.S.-nationwide prospective cohort studies, the Nurses' Health 
Study and the Health Professional Follow-up Study. These two studies offered a unique 
opportunity to integrate prospectively collected, regularly updated dietary intake data with 
tissue microbial features in incident colorectal cancers that occurred over long-term follow-
up.
METHODS
Study population
We used data drawn from two ongoing prospective cohort studies, the Nurses’ Health Study 
(NHS) and the Health Professionals Follow-up Study (HPFS). The NHS began in 1976 
among 121,700 U.S. female nurses aged 30 to 55 years at enrollment. The HPFS began in 
1986 among 51,529 U.S. male health professionals aged 40 to 75 years at enrollment. In 
both cohorts, participants have returned questionnaires every two years with follow-up rates 
exceeding 90% to provide information about lifestyle and dietary factors, medication use, 
and diagnoses of colorectal cancer and other diseases.
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A total of 137,217 individuals (47,449 men and 89,768 women) were included in this study. 
We excluded participants with implausibly high or low caloric intakes (i.e., <600 or >3,500 
kcal/day for women and <800 or >4,200 kcal/day for men), missing dietary pattern data, or 
with a history of ulcerative colitis or cancer (except for non-melanoma skin cancer) prior to 
baseline (1980 for the NHS and 1986 for the HPFS) (see eMethods). The Institutional 
Review Board at the Brigham and Women’s Hospital and Harvard T.H. Chan School of 
Public Health approved this study.
Assessment of diet
Participants reported average food intake over the preceding year (of each questionnaire 
return) through semi-quantitative food frequency questionnaires (FFQ), which have been 
previously validated and described.29 Total nutrient intake was calculated by summing 
intakes from all foods, and adjusted for total energy intake by the residual method. As 
previously described, total dietary fiber was calculated according to methods from the 
Association of Official Analytic Chemists.30 For this analysis, we used information from 
FFQs administered in following years: 1980, 1984, 1986, 1990, 1994, 1998, 2002, 2006, and 
2010 for the NHS, and 1986, 1990, 1994, 1998, 2002, 2006, and 2010 for the HPFS.
Assessment of colorectal cancer cases
In both cohorts, incident cases of colorectal cancer were reported by participants through 
2012 follow-up for the HPFS and NHS. We identified and confirmed lethal colorectal cancer 
cases through information from various sources including next-of-kin, the National Death 
Index, death certificates, and medical records. A study physician, blinded to exposure 
information, reviewed records and extracted data on histological type, anatomic location, 
and stage. We attempted to collect formalin-fixed paraffin-embedded (FFPE) tissue 
specimens from hospitals throughout the U.S. as previously detailed.9 Cases with available 
tissue data (n = 1,019) for the current study were similar to those without tissue data (n = 
2,241) with regard to patient and clinical characteristics (see eMethods).
Fusobacterium nucleatum analysis
DNA was extracted from colorectal cancer tissue obtained from sections of FFPE tumor 
blocks using QIAamp DNA FFPE tissue kits (Qiagen). We performed a real-time 
polymerase chain reaction (PCR) assay using custom TaqMan primer/probe sets (Applied 
Biosystems) for the nusG gene of F. nucleatum.9 The interassay coefficient of variation of 
cycle threshold (Ct) values from each of five selected specimens in five different batches was 
<1% for all targets in the validation study.14 F. nucleatum positivity was defined as a 
detectable level of F. nucleatum DNA within 45 PCR cycles, and F. nucleatum negativity as 
an undetectable level with a proper amplification of human reference gene SLCO2A1.
Statistical analyses
We used SAS software version 9.3 (SAS Institute Inc.) for all statistical analyses, and all 
statistical tests are two-sided. To account for multiple testing for the two primary hypotheses 
(related to Prudent and western dietary scores) associated with the two tumor subtype 
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variables, we adjusted the two-sided α level to .01 (≈ .05/4) by simple Bonferroni correction 
in our primary and secondary analysis.
Two maximally uncorrelated dietary patterns – one named “prudent” and another named 
“Western” – were derived by principal component analysis (PCA), as previously described 
and validated with good reproducibility.16,31 Factor loadings were derived based on the 
correlations between food groups and the two derived factors. Each participant was assigned 
a factor score, determined by adding the reported frequencies of food group intakes, 
weighted by the factor loadings. These factor scores were then standardized to have a mean 
of 0 and standard deviation of 1. To capture long-term habitual consumption, we calculated 
the cumulative average of the prudent (or Western) dietary pattern scores from preceding 
FFQs up to each questionnaire cycle. Then, the cumulative average score was categorized 
into sex-specific quartiles, and used as the primary exposure variable.
Using Cox proportional hazards models, we computed hazard ratios (HR) to examine the 
association of the prudent (or Western) dietary score with incidence of colorectal cancer. To 
test for trend, participants were assigned to the median score of their sex-specific dietary 
pattern quartile and then this variable was entered into the models as a continuous term. The 
covariates included in the multivariable models are described in Table 1 and the 
supplementary methods.
To examine whether the association between dietary patterns and incidence of colorectal 
cancer subgroups differed according to tissue F. nucleatum status, we used Cox proportional 
hazards regression models with a duplication method for competing risks data. As our 
primary hypothesis testing, we tested for heterogeneity by using a likelihood ratio test, 
comparing a model that allows for separate associations of dietary patterns and risk of 
cancer subgroups according to F. nucleatum status with a model that assumes a common 
association.32 In secondary analyses, we examined heterogeneity of the associations with 
cancer subgroups in relation to dominant factor loadings for the prudent dietary pattern 
using cumulative average intakes of fruits, vegetables, legumes, and whole grains as well as 
energy-adjusted intakes of fat, fiber, and protein, all of which were categorized into 
quartiles.
RESULTS
Two major, uncorrelated dietary patterns were identified by factor analysis. The prudent 
dietary pattern was characterized by high intake of vegetables, fruits, whole grains, and 
legumes, while the Western dietary pattern was characterized by red and processed meats, 
refined grains, and desserts (eTable 1). Consistent with prior analyses,16 participants with 
high prudent scores in the HPFS and NHS tended to smoke less, exercise more, and have 
greater rates of lower gastrointestinal endoscopy whereas Western pattern scores were 
associated with behaviors typically considered unhealthy (eTable 2).
After 26 years (in HPFS) and 32 years (in NHS) of follow-up encompassing 3,643,562 
person-years, we documented 1,019 incident colorectal cancers with available data on tissue 
F. nucleatum status. Among these cancer cases, there were 125 (12%) F. nucleatum-positive 
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tumors and 894 (88%) F. nucleatum-negative tumors. We examined the association of 
prudent and Western dietary pattern scores with incidence of overall colorectal cancer. 
Western dietary pattern scores showed a trend towards associations with overall risk of 
colorectal cancer in the HPFS (eTable 3), and the combined cohort (Table 1); however, 
statistical significance was not reached with the adjusted α level of.01. We did not observe 
significant heterogeneity in the associations of the dietary scores with colorectal cancer risk 
between the two cohorts (P ≥ .21). To maximize statistical power, we used the combined 
cohort for further analyses.
We then tested our primary hypothesis that the association of prudent and Western diets with 
colorectal cancer incidence might differ according to the presence of F. nucleatum in tumor 
tissue. Notably, the association between prudent dietary pattern and risk of colorectal cancer 
significantly differed by tumor F. nucleatum status (Pheterogeneity = .01) (Table 1). We found 
a significant inverse association of prudent dietary scores with F. nucleatum-positive cancer 
risk (Ptrend =.003), but not with F. nucleatum-negative cancer risk (Ptrend =.47). Comparing 
participants in the highest prudent dietary score quartile to those in the lowest quartile, the 
multivariable hazard ratio (HR) for F. nucleatum-positive tumors was 0.43 [95% confidence 
interval (CI), 0.25–0.72]; in contrast, the corresponding HR for F. nucleatum-negative 
tumors was 0.95 (95% CI, 0.77–1.17). We found similar differential associations by F. 
nucleatum status in men (HPFS) and women (NHS) though statistical power was limited 
(eTable 4). In addition, though statistical power was limited, we found similar results when 
levels of F nucleatum were categorized as low or high on the basis of the median cut point 
among F. nucleatum-positive cases, as performed in our previous analyses (eTable 5).9 As 
we observed that the fraction of colorectal cancers enriched with F. nucleatum gradually 
decreased from cecum to rectum,33 we conducted exploratory analyses stratified by tumor 
location (eTable 6). The differential association of prudent diet score with colorectal cancer 
by tissue F. nucleatum status appeared to be consistent in both proximal and distal cancer 
strata.
When we examined the association of the Western dietary pattern with colorectal cancer 
subgroups according to tumor F. nucleatum status, although Western dietary pattern scores 
appeared more strongly associated with F. nucleatum-positive cancer risk, there was no 
significant heterogeneity between the subgroups (Pheterogeneity = 0.23) (Table 1).
In a secondary analysis, we sought to determine if specific food groups might explain the 
observed differential associations between prudent dietary patterns and risk of colorectal 
cancer according to F. nucleatum status. We examined the top four dominantly contributing 
food groups to the prudent diet pattern (vegetables, fruits, legumes, and whole grains) in 
relation to the risk of colorectal cancer according to F. nucleatum status (eTable 7). We 
observed no significant heterogeneity (with the adjusted α of.01).
Finally, to further determine whether any specific macronutrient components of the prudent 
dietary pattern might explain the observed differential associations according to F. 
nucleatum status, we explored associations of fiber, fat, and protein intake with colorectal 
cancer subgroups (eTable 8). There appeared to be heterogeneity in the differential 
association of fiber intake with cancer subgroups classified by F. nucleatum status 
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(Pheterogeneity =.02), similar to the findings for prudent dietary pattern scores. Comparing 
participants in the highest quartile of fiber intake (>26 g per day for men and >19 g per day 
for women) to those in the lowest quartile (<18 per day for men and <13 g per day for 
women), the multivariable hazard ratio (HR) for F. nucleatum-positive tumors was 0.54 
[95% confidence interval (CI), 0.32–0.92]; in contrast, the corresponding HR for F. 
nucleatum-negative tumors was 1.13 (95% CI, 0.92–1.40). In further exploratory analyses, 
we found that intakes of cereal-derived fiber might be differentially associated with 
colorectal cancer according to F. nucleatum status (Pheterogeneity =.01) (eTable 9). We did not 
observe such heterogeneity for fat or protein.
DISCUSSION
In the two U.S.-nationwide prospective cohorts, we found that participants with higher long-
term prudent dietary pattern scores were associated with a lower risk of F. nucleatum-
positive colorectal cancers but not F. nucleatum-negative cancers. Our data also suggest that 
higher intakes of dietary fiber, one of the components of the prudent diet, may be associated 
with a lower risk of F. nucleatum-positive colorectal cancer but not F. nucleatum-negative 
cancer. These findings support the hypothesis that the possible cancer-preventative effects of 
prudent diets rich in dietary fiber may be mediated by modulation of specific species in the 
gut microbiota, and subsequent alteration of the amount of F. nucleatum in local colonic 
tissue. To our knowledge, our study represents the first to examine the intersection of diet 
and incidence of colorectal cancer subgroups according to microbial status in human tumor 
tissue.
The potential role of diet in modulating the risk of a variety of diseases including colorectal 
cancer has been widely recognized23,34 According to the World Cancer Research Fund and 
American Institute for Cancer Research, foods with fiber including whole grains are one of 
the strongest factors linked to decreasing the risk of colorectal cancer.35 Importantly, 
however, there has been considerable heterogeneity in the epidemiological data associating 
prudent dietary patterns and its major components with colorectal cancer.36 Our results here 
suggest that the inconsistency in the association of prudent dietary patterns (and its 
components) with lower colorectal cancer risk may be in part due to differential associations 
with cancer subgroups according to F. nucleatum in tumor tissue. In addition, given our 
recent findings between increasing amounts of F. nucleatum DNA in colorectal cancer tissue 
and worsened survival,14 our data lends additional support to the promotion of healthy diets 
to reduce mortality from colorectal cancer.
The precise mechanism by which prudent diets rich in dietary fiber may lower F. nucleatum-
enriched cancer incidence remains unclear. Accumulating evidence suggests that long-term 
dietary fiber intake has a profound impact on the gut microbiome, specifically through 
promotion of microbial diversity and by lowering levels of inflammatory metabolites.25,37–40 
Of note, a recent study showed that a two-week feeding intervention switching rural-
dwelling South Africans from a high-fiber, low-fat diet to a low-fiber, high-fat diet was 
associated with an increase in F. nucleatum measured by PCR in the stool.24 In addition, 
some have hypothesized that the variation observed in F. nucleatum levels in colorectal 
cancers collected from Spain, Vietnam, Japan, and the U.S. may be due to differences in 
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dietary practices in these countries.5,41 Furthermore, in a cross sectional study, participants 
with advanced adenoma were associated with lower dietary fiber intakes as well as distinct 
fecal microbiome communities when compared to healthy controls.42 It is plausible that 
abundance of microbiota-accessible carbohydrates from prudent diets may influence 
bacterial fermentation of dietary fiber resulting in altered levels of short-chain fatty acids. 
These changes may alter pH, increase transit time of gut contents, or lead to differences in 
local immune surveillance, which are less hospitable for non-native species such as F. 
nucleatum to establish themselves in the colonic niche and potentiate colorectal 
carcinogenesis.24,25,43,44 Taken together, these data provide evidence for substantial 
influences of diet on the gut microbiome, which may in turn influence tumorigenesis.
There are several strengths in this study. First, our dietary data were prospectively collected 
and have been well-validated.29 Second, our data were detailed and updated such that we 
could examine long-term effects of overall dietary patterns, specific food groups, and 
macronutrients in relation to colorectal cancer risk. Third, we collected detailed data on 
multiple potential confounders, although residual confounding cannot be excluded. Finally, 
our molecular pathological epidemiology (MPE) research45 provides refined risk estimates 
for specific cancer subgroups such as F. nucleatum-positive cancer, and thereby offers 
insights into pathogenesis and causality. Notably, molecular subtyping in the MPE approach 
can gather pathogenetically similar cases, and thus can enhance statistical inference (even 
with a relatively small number of cases).46 The current study represents emerging unique 
microbial MPE research,47 where the microbial feature in tumor tissue can serve as a 
pathogenic signature.
We acknowledge limitations of this study. First, this study is observational, and residual 
confounding may be an issue. Nevertheless, adjustment for a variety of known risk factors 
for colorectal cancer showed no substantial impact on our results. Second, our diet data were 
derived from food frequency questionnaires (FFQ), and subject to measurement errors. 
Nonetheless, studies have shown that FFQ can better capture long-term dietary intakes than 
detailed diet diaries in a limited period.48 Third, with the use of FFPE tissue specimens, 
routine histopathology procedures might have influenced performance characteristics of our 
PCR assay to detect F. nucleatum. Nonetheless, we conducted a rigorous validation study, 
which showed high precision of our PCR assay to detect F. nucleatum.9 Moreover, our assay 
has previously been shown to have high specificity for F. nucleatum.6 Fourth, we could not 
collect FFPE blocks from all colorectal cancer cases in the cohorts; nonetheless, cases with 
available tissue were generally similar to those without tissue with regard to patient 
characteristics. Fifth, because our participants were all health professionals and mostly 
white, generalizability of our findings to other populations need to be examined in future 
studies.
In summary, we have shown that prudent diet is associated with a lower risk of F. 
nucleatum-positive colorectal cancer but not F. nucleatum-negative cancer. Our data generate 
new hypotheses about how the intestinal microbiota may mediate the association between 
diet and colorectal neoplasms. Further studies are needed to confirm these findings and 
determine the potential utility of characterization of F. nucleatum in colonic mucosa, tumor, 
or stool as a biomarker for personalized nutritional, probiotic or antibiotic interventions. In 
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addition, our findings underscore the importance of future large-scale prospective studies 
that examine the gut microbiota to understand the complex intersection of diet, the gut 
microbiome, and carcinogenesis.49
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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